Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

GRAIL, LLC (GRAL)GRAL

Upturn stock ratingUpturn stock rating
GRAIL, LLC
$15.09
Delayed price
Profit since last BUY0%
Consider higher Upturn Star rating
upturn advisory
BUY since 7 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: GRAL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 0%
Upturn Advisory Performance Upturn Advisory Performance5
Avg. Invested days: 7
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 0%
Avg. Invested days: 7
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance5

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 496.96M USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -58.29
Volume (30-day avg) 587033
Beta -
52 Weeks Range 12.33 - 23.36
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 496.96M USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -58.29
Volume (30-day avg) 587033
Beta -
52 Weeks Range 12.33 - 23.36
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-13
When -
Estimate -6.43
Actual -3.5027
Report Date 2024-11-13
When -
Estimate -6.43
Actual -3.5027

Profitability

Profit Margin -
Operating Margin (TTM) -640.47%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -284404583
Price to Sales(TTM) 4.22
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 33600800
Shares Floating 21619290
Percent Insiders 13.75
Percent Institutions 66.53
Trailing PE -
Forward PE -
Enterprise Value -284404583
Price to Sales(TTM) 4.22
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 33600800
Shares Floating 21619290
Percent Insiders 13.75
Percent Institutions 66.53

Analyst Ratings

Rating 3
Target Price -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Rating 3
Target Price -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -

About GRAIL, LLC

Exchange NASDAQ Headquaters Menlo Park, CA, United States
IPO Launch date 2024-06-25 CEO & Director Mr. Robert P. Ragusa
Sector Healthcare Website https://grail.com
Industry Diagnostics & Research Full time employees 1360
Headquaters Menlo Park, CA, United States
CEO & Director Mr. Robert P. Ragusa
Website https://grail.com
Website https://grail.com
Full time employees 1360

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​